ArticleTranslational oncology2026
Molecular characterization of cell dynamics during osteosarcoma progression.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteosarcoma is the most common malignant bone disease. The current clinical treatment is difficult to deal with the high heterogeneity within tumors and the cellular dynamic remodeling during the metastasis process of osteosarcoma.
methodsCell annotation was performed using the SingleR algorithm in combination with specific marker genes. Further subcluster analysis was conducted on osteoblasts, myeloid cells, fibroblasts, malignant cells and T/NK cells. Cell differentiation trajectories were constructed using Monocle2 and scTour for pseudotime analysis. The spatial transcriptome data was deconvolved using the CARD algorithm to verify the spatial distribution of cells.
resultsCompared with primary tumors, the microenvironment of metastatic tumors undergoes significant remodeling, manifested as a significant increase in the proportions of fibroblasts, mast cells and T/NK cells, while the proportions of osteoblasts and myeloid cells decrease. Spatial bifurcation pattern revealed a divergent evolutionary path from subtype 2 to other subtypes as the metastatic state. It identified YY1 in subtype2 as a spatial regulator of IER5L in the osteosarcoma microenvironment. The study also observed the reprogramming of immune cells and stromal cells in metastatic foci. In particular, the differentiation trajectory of TAMs (SLC40A1 → MT1G → CXCL10) suggests that macrophages undergo functional transformation during tumor progression under an immunosuppressive microenvironment.
conclusionIt is the most forward time for the large-scale integration of multi-center single-cell data and spatial transcriptomics profiles covering the primary, recurrent and metastatic stages, systematically depicting the dynamic changes in cell composition during the progression of osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.